Beam Therapeutics Inc is trading 4.3% up at $32.33 as the stock extends its recent gains following positive Wall Street commentary and new analyst coverage.
- Jefferies initiated coverage with a Buy rating, citing multiple clinical data catalysts expected between 2025 and 2026.
- H.C. Wainwright and Clear Street maintain Buy ratings with price targets reaching as high as $80, reinforcing strong bullish sentiment.
- The upward momentum is supported by growing investor confidence in the company's long-term clinical pipeline and upcoming data readouts.